Poolbeg Pharma (LON:POLB) Trading 13.3% Higher – Time to Buy?

Poolbeg Pharma PLC (LON:POLB) shares traded up 13.3% on Tuesday . The stock traded as high as GBX 4.70 and last traded at GBX 4.70. 812,935 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 1,294,316 shares. The stock had previously closed at GBX 4.15.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Wednesday, January 28th.

Poolbeg Pharma Price Performance

The stock has a market cap of £33.14 million, a P/E ratio of -4.12 and a beta of 2.00. The company has a fifty day moving average price of GBX 4.39 and a 200 day moving average price of GBX 4.07.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.